Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Active-controlled, Multi-center Phase II Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease

NCT04282954 is registered in ClinicalTrials.gov with Onconic Therapeutics Inc. as lead sponsor.

NCT NCT04282954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04282954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Active-controlled, Multi-center Phase II Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease
Lead sponsor
Onconic Therapeutics Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 15, 2019
Completion date
December 11, 2020
Enrollment
188 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gerd